Download PDF
CC BY 4.0 · Brazilian Journal of Oncology 2022; 18: e-20220353
DOI: 10.5935/2526-8732.20220353
Case Report
Clinical Oncology

Delayed and sequencial hemolytic uremic syndrome as a complication of Gemcitabine therapy

Síndrome hemolítico-urêmica tardia e sequencial como complicação da terapia com gemcitabina
Thaís Sampaio Corrêa de Almeida 
1   Instituto D´Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil, Clinical Oncology - São Paulo - São Paulo - Brazil
,
Renata Colombo Bonadio
1   Instituto D´Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil, Clinical Oncology - São Paulo - São Paulo - Brazil
,
Rafaela Lopes da Silva Naves
1   Instituto D´Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil, Clinical Oncology - São Paulo - São Paulo - Brazil
,
Paulo Henrique Amor-Divino
1   Instituto D´Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil, Clinical Oncology - São Paulo - São Paulo - Brazil
,
Paulo Marcelo Gehm Hoff
1   Instituto D´Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil, Clinical Oncology - São Paulo - São Paulo - Brazil
› Author Affiliations Financial support: None to declare.
› Further Information
   Permissions and Reprints All articles of this category

ABSTRACT

Gemcitabine is a widely used drug in the treatment of diverse malignancies and its use has been approved by the US Food and Drug Administration. This drug has been associated with a rare adverse event, the Hemolytic Uremic Syndrome (HUS), characterized by acute kidney injury, microangiopathic hemolytic anemia, and thrombocytopenia. The purpose of this report is to draw attention to an atypical manifestation of this severe and unusual complication, and discuss its management and outcome. We report a 70-year-old woman with Li-Fraumeni syndrome diagnosed with pancreatic adenocarcinoma and leiomyosarcoma, whom after fourteen cycles of therapy with gemcitabine and nab-paclitaxel, with good disease control, developed clinical manifestation of atypical HUS with exuberant pulmonary symptoms, followed by hemolytic anemia, and acute renal failure presenting on an unusual sequential fashion. The case highlights the importance of maintaining a high suspicion for SHU in patients receiving gemcitabine, being aware that delayed and atypical manifestations may occur.

RESUMO

A gencitabina é um fármaco amplamente utilizado no tratamento de diversas neoplasias e seu uso foi aprovado pelo FDA dos Estados Unidos desde 1994. Esse fármaco tem sido associado a um evento adverso raro, a síndrome hemolítico-urêmica (SHU), caracterizada por lesão renal aguda, anemia hemolítica microangiopática e trombocitopenia. O objetivo deste relato é chamar a atenção para uma manifestação atípica dessa complicação grave e incomum e discutir seu manejo e desfecho. Relatamos o caso de uma mulher de 70 anos com síndrome de Li-Fraumeni diagnosticada com adenocarcinoma pancreático e leiomiossarcoma, que após quatorze ciclos de terapia com gencitabina e nab-paclitaxel, com bom controle da doença, desenvolveu manifestação clínica de SHU atípica com sintomas pulmonares exuberantes, seguido por anemia hemolítica e insuficiência renal aguda apresentando-se de forma sequencial incomum. O caso destaca a importância de manter uma alta suspeita de SHU em pacientes que recebem gencitabina, estando ciente de que podem ocorrer manifestações tardias e atípicas.

Keywords:

Pancreatic Neoplasms - Hemolytic-Uremic Syndrome - Drug Therapy

Descritores:

Neoplasias pancreáticas - Síndrome hemolítico-urêmica - Terapia medicamentosa

CONFLICTS OF INTEREST

RCB: Speaker fees and/or honoraria for consultancy or advisory functions: AstraZeneca; Financial support for educational programs and symposia: AstraZeneca, Daichii-Sankyo; Institutional Research Funding: Novartis, AstraZeneca, GSK.

PHAD: Speaker fees and/or honoraria for consultancy or advisory functions: AstraZeneca.


TRIAL REGISTRATION

This case report was submitted and approved for committee of ethic in research of Hospital e Maternidade São Luiz. Registration number: 5.414.155


FINANCIAL CONFLICT OF INTEREST

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.




Publication History

Received: 23 May 2022

Accepted: 10 June 2022

Article published online:
22 September 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

Bibliographical Record
Thaís Sampaio Corrêa de Almeida, Renata Colombo Bonadio, Rafaela Lopes da Silva Naves, Paulo Henrique Amor-Divino, Paulo Marcelo Gehm Hoff. Delayed and sequencial hemolytic uremic syndrome as a complication of Gemcitabine therapy. Brazilian Journal of Oncology 2022; 18: e-20220353.
DOI: 10.5935/2526-8732.20220353
 

  • REFERENCES

  • 1 Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; Aug; 347 (08) 589-600
    Search in Google Scholar
  • 2 Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr [Internet] 1955; Sep; 85 (38-39): 905-909 [cited 2022 Apr 25]; Available from: https://pubmed.ncbi.nlm.nih.gov/13274004/
    Search in Google Scholar
  • 3 Saif MW, McGee PJ. Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature. J Pancreas [Internet] 2005; Jul; 6 (04) 369-374 [cited 2022 Mar 28]; Available from: https://pubmed.ncbi.nlm.nih.gov/16006690/
    Search in Google Scholar
  • 4 Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer [Internet] 1999; May; 85 (09) 2023-2032 [cited 2022 Mar 28]; Available from: https://pubmed.ncbi.nlm.nih.gov/10223245/
    Search in Google Scholar
  • 5 Lee HW, Chung MJ, Kang H, Choi H, Choi YJ, Lee KJ. et al. Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature. Gut Liver [Internet] 2014; Jun; 8 (01) 109-112 [cited 2022 Apr 25]; Available from: https://pubmed.ncbi.nlm.nih.gov/24516709/
    Search in Google Scholar
  • 6 Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer [Internet] 1999; May; 85 (09) 2023-2032 [cited 2022 Mar 28]; Available from: https://pubmed.ncbi.nlm.nih.gov/10223245/
    Search in Google Scholar
  • 7 Desramé J, Duvic C, Bredin C, Béchade D, Artru P, Brézault C. et al. Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature. Rev Med Interne [Internet] 2005; Mar; 26 (03) 179-188 [cited 2022 Mar 28]; Available from: https://pubmed.ncbi.nlm.nih.gov/15777580/
    Search in Google Scholar
  • 8 Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD. et al. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs [Internet] 1994; 12 (01) 29-34 [cited 2022 Mar 28]; Available from: https://pubmed.ncbi.nlm.nih.gov/7960602/
    Search in Google Scholar
  • 9 Müller S, Schütt P, Bojko P, Nowrousian MR, Hense J, Seeber S. et al. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Ann Hematol [Internet] 2005; Feb; 84 (02) 110-114 [cited 2022 Mar 28]; Available from: https://pubmed.ncbi.nlm.nih.gov/15340761/
    Search in Google Scholar
  • 10 Izzedine H, Isnard-Bagnis C, Launay-Vacher V, Mercadal L, Tostivint I, Rixe O. et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant [Internet] 2006; Sep; 21 (11) 3038-3045 [cited 2019 Aug 23]; Available from: https://academic.oup.com/ndt/article/21/11/3038/1877827
    Search in Google Scholar
  • 11 Ruiz I, Del Valle J, Gómez A. Gemcitabine and haemolytic-uraemic syndrome. Ann Oncol 2004; Oct; 15 (10) 1575-1576
    Search in Google Scholar
  • 12 Zupancic M, Shah PC, Shah-Khan F. Gemcitabineassociated thrombotic thrombocytopenic purpura. Lancet Oncol [Internet] 2007; Jul; 8 (07) 634-641 [cited 2022 Mar 28]; Available from: https://pubmed.ncbi.nlm.nih.gov/17613425/
    Search in Google Scholar
  • 13 Al Ustwani O, Lohr J, Dy G, Levea C, Connolly G, Arora P. et al. Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. J Gastrointest Oncol [Internet] 2014; Feb; 5 (01) E30-E33 [cited 2022 Mar 28]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904030/
    Search in Google Scholar
  • 14 Rieger M, Mannucci PM, Hovinga JAK, Herzog A, Gerstenbauer G, Konetschny C. et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; Aug; 106 (04) 1262-1267
    Search in Google Scholar
  • 15 Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F. et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 2005; May; 16 (05) 1177-1183
    Search in Google Scholar
  • 16 Leal F, Macedo LT, Carvalheira JBC. Gemcitabinerelated thrombotic microangiopathy: a single-centre retrospective series. J Chemother [Internet] 2014; Jun; 26 (03) 169-172 [cited 2022 Mar 28]; Available from: https://pubmed.ncbi.nlm.nih.gov/24091354/
    Search in Google Scholar
  • 17 Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P. Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome. Pathol Biol (Paris) 2015; Jun; 63 (03) 136-143
    Search in Google Scholar
  • 18 Cidon EU, Martinez PA, Hickish T. Gemcitabineinduced haemolytic uremic syndrome, although infrequent, can it be prevented: a case report and review of literature. World J Clin Cases [Internet] 2018; Oct; 6 (12) 531-537 [cited 2022 Mar 28]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212612/
    Search in Google Scholar
  • 19 Bharthuar A, Egloff L, Becker J, George M, Lohr JW, Deeb G. et al. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report. Cancer Chemother Pharmacol [Internet] 2009; Jun; 64 (01) 177-181 [cited 2022 Mar 28]; Available from: https://pubmed.ncbi.nlm.nih.gov/19116715/
    Search in Google Scholar
  • 20 Gourley BL, Mesa H, Gupta P. Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) with rituximab. Cancer Chemother Pharmacol 2010; Jan; 65 (05) 1001-1004
    Search in Google Scholar
  • 21 Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; Aug; 26 (08) 1325-1329
    Search in Google Scholar